.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Chubb
UBS
Cipla
Covington
AstraZeneca
Dow
Mallinckrodt
QuintilesIMS
Medtronic

Generated: July 23, 2017

DrugPatentWatch Database Preview

ESKALITH Drug Profile

« Back to Dashboard

Which patents cover Eskalith, and when can generic versions of Eskalith launch?

Eskalith is a drug marketed by Noven Therap and Jds Pharms and is included in three NDAs.

The generic ingredient in ESKALITH is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.

Summary for Tradename: ESKALITH

Patents:0
Applicants:2
NDAs:3
Bulk Api Vendors: see list56
Clinical Trials: see list9
Patent Applications: see list80
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ESKALITH at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Noven Therap
ESKALITH
lithium carbonate
CAPSULE;ORAL016860-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Jds Pharms
ESKALITH
lithium carbonate
TABLET;ORAL017971-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Jds Pharms
ESKALITH CR
lithium carbonate
TABLET, EXTENDED RELEASE;ORAL018152-001Mar 29, 1982DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Farmers Insurance
Queensland Health
McKinsey
Dow
AstraZeneca
UBS
Medtronic
QuintilesIMS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot